Lung cancer, comorbidities, and medication: the infernal trio

Lung cancer, comorbidities, and medication: the infernal trio

Most patients with lung cancer are smokers and are of advanced age. They are therefore at high risk of having age- and lifestyle-related comorbidities. These comorbidities are subject to treatment or even polypharmacy. There is growing evidence of a link between lung cancer, comorbidities and medica...

Descripció completa

Dades bibliogràfiques
Autors principals:	Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart
Format:	Article
Idioma:	English
Publicat:	Frontiers Media S.A. 2024-02-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	comorbidities lung cancer survival polypharmacy drug-drug interaction
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1016976/full

Ítems similars

Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients
per: Hélène Pluchart, et al.
Publicat: (2023-06-01)

Comparison of seven comorbidity scores on four-month survival of lung cancer patients
per: Hélène Pluchart, et al.
Publicat: (2023-11-01)

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
per: Hélène Pluchart, et al.
Publicat: (2017-07-01)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
per: Thomas Pierret, et al.
Publicat: (2022-04-01)

Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance of the tumor board decision in the era of immunotherapy
per: Justin Benet, et al.
Publicat: (2022-01-01)

Clinical evaluation of pharmacists’ interventions on multidisciplinary lung transplant outpatients’ management: results of a 7-year observational study
per: Boubou Camara, et al.
Publicat: (2020-11-01)

Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine
per: Julian Pinsolle, et al.
Publicat: (2019-10-01)

Development of Indirect Health Data Linkage on Health Product Use and Care Trajectories in France: Systematic Review
per: Florence Ranchon, et al.
Publicat: (2023-05-01)

Electronic pharmaceutical record for best possible medication history at preoperative evaluation to prevent postoperative adverse events: a quasi-experimental study
per: Pierre Albaladejo, et al.
Publicat: (2025-03-01)

Pharmacy Education and Clinical Pharmacy Training in France
per: Florence Ranchon, et al.
Publicat: (2024-10-01)

Clinical, economic and organizational impact of pharmacist interventions on injectable antineoplastic prescriptions: a prospective observational study
per: Céline Zecchini, et al.
Publicat: (2020-02-01)

Information and Communication Technologies in Lung Transplantation: Perception of Patients and Medical Teams
per: Sébastien Chanoine, et al.
Publicat: (2022-06-01)

Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex
per: Renan Le Cras, et al.
Publicat: (2023-12-01)

Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer
per: Anne‐Sophie Hatat, et al.
Publicat: (2022-10-01)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
per: Jean-Baptiste Assié, et al.
Publicat: (2020-10-01)

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
per: Ali Chour, et al.
Publicat: (2024-09-01)

Interprofessional safety reporting and review of adverse events and medication errors in critical care
per: Chapuis C, et al.
Publicat: (2019-04-01)

Interplay Between Membrane Permeability and Enzymatic Barrier Leads to Antibiotic-Dependent Resistance in Klebsiella Pneumoniae
per: Marie-Helene Nicolas-Chanoine, et al.
Publicat: (2018-06-01)

Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial
per: Lorène Zerah, et al.
Publicat: (2021-10-01)

COVID-19 mass vaccination – an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns
per: Roseline Mazet, et al.
Publicat: (2022-12-01)

Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies
per: Quentin Perrier, et al.
Publicat: (2021-04-01)

Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units
per: Claire Chapuis, et al.
Publicat: (2022-12-01)

Adverse Drug Reactions in Multimorbid Older People Exposed to Polypharmacy: Epidemiology and Prevention
per: Siobhán McGettigan, et al.
Publicat: (2024-04-01)

A study of harmful drug–drug interactions due to polypharmacy in hospitalized patients in Goa Medical College
per: Akshay Khandeparkar, et al.
Publicat: (2017-01-01)

Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study.
per: Pierrick Bedouch, et al.
Publicat: (2012-01-01)

Correction: Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study.
per: Pierrick Bedouch, et al.
Publicat: (2013-01-01)

A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection
per: Quentin Perrier, et al.
Publicat: (2021-01-01)

Polypharmacy: An Overview
per: Nelisa Paidamwoyo Ganga
Publicat: (2022-12-01)

Imaging and screening in lung cancer
per: Matteo Giaj Levra, et al.
Publicat: (2008-12-01)

Potential drug-drug interactions in hospitalized patients with COVID-19.
per: Danuta Szkutnik-Fiedler, et al.
Publicat: (2023-06-01)

Analysis of Burden and Outcomes of Oral Hypoglycaemic Agent Induced Adverse Drug Effects at a Tertiary Care Centre
per: Kavita S Joshi, et al.
Publicat: (2022-05-01)

Survey of polypharmacy prescription in a tertiary care Hospital, Belagavi
per: Suma Sukumaran, et al.
Publicat: (2021-11-01)

Studi Potensi Interaksi Obat pada Resep Polifarmasi di Dua Apotek Kota Bandung
per: Irianti Bahana Maulida Reyaan, et al.
Publicat: (2021-09-01)

Evaluation of Potential Drug - Drug Interactions in General Medicine Ward of Teaching Hospital in Southern India
per: Akram Ahmad, et al.
Publicat: (2015-02-01)

A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit
per: Shipra Jain, et al.
Publicat: (2017-03-01)

Recognizing and preventing unacknowledged prescribing errors associated with polypharmacy
per: Giovanna Gentile, et al.
Publicat: (2024-09-01)

Polypharmacy and Potential Drug Interactions Causing Neurological Symptoms in Geriatric Patients with Epilepsy
per: Bahar Erbaş
Publicat: (2022-09-01)

Polypharmacy in Osteoporosis Patients
per: Yavuz Ali Karahan, et al.
Publicat: (2015-04-01)

Polypharmacy in the elderly
per: Negar Golchin, et al.
Publicat: (2015-01-01)

Drug prescription in the elderly
per: Paola Fuentes, et al.
Publicat: (2013-05-01)